VVOS · Vivos Therapeutics, Inc.
$0.31
-0.03 (-9.29%)
At close · Aug 17
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Without additional financing, these factors raise substantial doubt regarding the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$6.91M
Shares
20.12M
Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.
Fails to Deliver History
| Settlement Date | Quantity | Price | Value |
|---|---|---|---|
| 2026-07-31 | 4,800 | $0.41 | $1,968 |
| 2026-07-29 | 3,571 | $0.42 | $1,500 |
| 2026-07-24 | 1,454 | $0.39 | $567 |
| 2026-07-21 | 1,692 | $0.41 | $694 |
| 2026-07-20 | 3,317 | $0.42 | $1,393 |
| 2026-07-17 | 7,326 | $0.41 | $3,004 |
| 2026-07-16 | 579 | $0.41 | $237 |
| 2026-07-09 | 14,111 | $0.48 | $6,773 |
| 2026-07-08 | 24,881 | $0.48 | $11,943 |
| 2026-07-07 | 7,569 | $0.48 | $3,633 |
| 2026-07-06 | 80,612 | $0.45 | $36,275 |
| 2026-07-02 | 114,521 | $0.50 | $57,261 |
| 2026-07-01 | 195,627 | $0.45 | $88,032 |
| 2026-06-30 | 16,976 | $0.49 | $8,318 |
| 2026-06-25 | 57,659 | $0.44 | $25,370 |
| 2026-06-24 | 207,345 | $0.47 | $97,452 |
| 2026-06-23 | 213,653 | $0.40 | $85,461 |
| 2026-06-22 | 6,208 | $0.50 | $3,104 |
| 2026-06-15 | 13,135 | $0.57 | $7,487 |
| 2026-06-11 | 9,830 | $0.64 | $6,291 |
| 2026-06-10 | 13,191 | $0.70 | $9,234 |
| 2026-06-09 | 195,360 | $0.87 | $169,963 |
| 2026-06-08 | 547,867 | $0.86 | $471,166 |
| 2026-06-04 | 98,977 | $0.64 | $63,345 |
| 2026-06-03 | 140,059 | $0.68 | $95,240 |
| 2026-06-02 | 3,346 | $0.69 | $2,309 |
| 2026-05-29 | 13,069 | $0.67 | $8,756 |
| 2026-05-22 | 63 | $0.58 | $37 |
| 2026-05-21 | 18,699 | $0.59 | $11,032 |
| 2026-05-20 | 18,698 | $0.59 | $11,032 |
| 2026-05-19 | 21,878 | $0.60 | $13,127 |
| 2026-05-18 | 18,698 | $0.64 | $11,967 |
Showing 1–32 of 32 settlements
Key facts
CIK
1716166
CUSIP
92859E207
13F (30d)
21 filings
21 filers
Visit website
Investor relations